• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Quantification of the total neuraminidase content of recent commercially-available influenza vaccines: Introducing a neuraminidase titration reagent

tetano

Editor, Senior Moderator
Vaccine. 2019 Dec 6. pii: S0264-410X(19)31570-1. doi: 10.1016/j.vaccine.2019.11.041. [Epub ahead of print] [h=1]Quantification of the total neuraminidase content of recent commercially-available influenza vaccines: Introducing a neuraminidase titration reagent.[/h]
Gao Z[SUP]1[/SUP], Robinson K[SUP]1[/SUP], Skowronski DM[SUP]2[/SUP], De Serres G[SUP]3[/SUP], Withers SG[SUP]4[/SUP].
[h=3]Author information[/h] 1 Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, B.C. V6T 1Z1, Canada. 2 School of Population and Public Health, University of British Columbia, 2206 E Mall, Vancouver, British Columbia V6T 1Z3, Canada; Communicable Diseases and Immunization Services, British Columbia Centre for Disease Control, 655 West 12th Ave, Vancouver, British Columbia, Canada. 3 Department of Biological and Occupational Risks, Institut National de Sant? Publique du Qu?bec, Qu?bec, Canada; Department of Social and Preventive Medicine, Laval University, Qu?bec, Canada. 4 Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, B.C. V6T 1Z1, Canada. Electronic address: withers@chem.ubc.ca.

[h=3]Abstract[/h] The protective immunological effects of the influenza neuraminidase (NA) surface protein are of renewed interest but NA content in vaccines remains unstandardized and methods to easily and reliably quantify NA content are unsatisfactory. We describe the use of a recently developed fluorometric titration reagent, TR1, to efficiently quantify the total enzymatically active NA content of six commercially-available influenza vaccines, including split/subunit, inactivated/live and standard /high dose products distributed from 2015/16 to 2017/18 in North America. Considerable differences in active NA content were measured between influenza vaccine products for the same season, with relative content differences between brands generally maintained across seasons. These results highlight the simplicity of use of this reagent, and its unique ability to quantitate enzymatically active NA without the need for specific activities of individual enzymes. The reagent could also prove valuable in assessing the importance of using fully active enzyme to generate protective immune responses.
Copyright ? 2019 Elsevier Ltd. All rights reserved.


[h=4]KEYWORDS:[/h] Active-site titration; HA and NA levels in vaccines; Neuraminidase content

PMID: 31818533 DOI: 10.1016/j.vaccine.2019.11.041
 
Back
Top Bottom